Healios KK 6VX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €1.56
- Day Range
- €1.54–1.54
- 52-Week Range
- €1.33–18.75
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 135.00M
- Market Cap
- ¥207.90M
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 270.19
- Price/Sales
- 597.51
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 102
- Website
- https://www.healios.co.jp
Valuation
|
Metric
|
6VX
|
|---|---|
Price/Earnings (Normalized) | 270.19 |
Price/Book Value | 5.16 |
Price/Sales | 597.51 |
Price/Cash Flow | — |
Price/Earnings
6VX
Financial Strength
|
Metric
|
6VX
|
|---|---|
Quick Ratio | 1.95 |
Current Ratio | 2.05 |
Interest Coverage | — |
Quick Ratio
6VX
Profitability
|
Metric
|
6VX
|
|---|---|
Return on Assets (Normalized) | 1.08% |
Return on Equity (Normalized) | 4.41% |
Return on Invested Capital (Normalized) | −39.88% |
Return on Assets
6VX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|wN&<#^w | LOCK|Nr&pH | $126B | |||
| Moderna Inc
MRNA
| LOCK|F!&hmr | LOCK|Vvt | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|JJswRd> | LOCK|rD^W | $80B | |||
| argenx SE ADR
ARGX
| LOCK|T@Y>@X | LOCK|M^ | $53B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|jK?%JTx | LOCK|$L | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Fx@B>< | LOCK|$#BH | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|lhsJ%p% | LOCK|$Lqsw | $26B | |||
| Incyte Corp
INCY
| LOCK|@Z#sqZ# | LOCK|wn | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|tHFbn& | LOCK|!% | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#gvdd$ | LOCK|khx | $14B |
United States